Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsRaw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tg Therapeutics (TGTX) Short term Debt (2020 - 2021)

Historic Short term Debt for Tg Therapeutics (TGTX) over the last 2 years, with Q4 2021 value amounting to $975000.0.

  • Tg Therapeutics' Short term Debt fell 9560.39% to $975000.0 in Q4 2021 from the same period last year, while for Dec 2021 it was $975000.0, marking a year-over-year decrease of 9560.39%. This contributed to the annual value of $975000.0 for FY2021, which is 9560.39% down from last year.
  • According to the latest figures from Q4 2021, Tg Therapeutics' Short term Debt is $975000.0, which was down 9560.39% from $16.0 million recorded in Q3 2021.
  • Tg Therapeutics' 5-year Short term Debt high stood at $30.1 million for Q1 2021, and its period low was $975000.0 during Q4 2021.